

PERSONAL INFORMATION

Loredana Sarmati



Tor Vergata University
Department of System Medicine
V. Cracovia n, 50, 00133, Rome, Italy
+390672596873 +393478144604
sarmati@med.uniroma2.it
State personal website(s)

Sex F | 13/08/1957 | Nationality Italian

Table with 3 columns: Enterprise, University, and EPR. It contains checkboxes for various professional levels such as Management Level, Full professor, Associate Professor, etc.

WORK EXPERIENCE

Replace with dates (from - to)

2022 Head of Infectious Disease Clinic, Policlinco Tor Vergata, Rome, Italy
2022 to present Coordinator of Medical and Surgery Degree course, Tor Vergata University
2021 to present Full Professor Infectious Diseases, Tor Vergata University
2018 to present President Lazio section of Italian Society of Infectious Diseases
2014 to 2021 Associate Professor Of Infectious Diseases at Tor Vergata Hospital, Rome, Italy
2009-2012 Head of the Quality of the UOC of Infectious Diseases, Tor Vergata University, Rome Italy (Qualitas Project, the Italian Society of Infectious Diseases)

EDUCATION AND TRAINING

1992 Infectious diseases specialist with honour
1989 Researcher in Clinical Infectious Disease, University Tor Vergata, Rome, Italy
1988 Specialist in Internal Medicine with honour
1986-87 Winner of 2 annual scholarships of the Italian National Association for the fight against AIDS
1984 From May to December Fellowship at the National Institute of Health on a research study in immunity against tetanus
1983 Bachelors degree with honors in Medicine and Surgery at the University "La Sapienza", Rome, Italy

WORK ACTIVITIES

Awards: 2015 Fellowship Programme Gilead, 2017 Fellowship Programme Gilead, 2020 Fellowship Programme Gilead
Editorial activity: 2019 Editorial board member Virology (MDPI), 2019 Editorial board member Microorganisms, 2020 Editorial board member Journal of Clinical Medicine (MDPI)
Invited presentations
Grants: 2015 Fellowship Programme Gilead

2017 Fellowship Programme Gilead
 2020 Fellowship Programme Gilead
 2020 Bando PRIN Miur

ADDITIONAL INFORMATION

Publications 238 publications in peer-review journals
 total number of citations: 3855
 H index 33 (Scopus)

Relevant publications

- Sarmati L, Ercoli L, Parisi SG, Rocchi G, Giannini G, Galluzzo C, Vella S, Andreoni M. High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment. *J Acquir Immune Defic Syndr*. 1994;7(1):10-4. PMID: 8263748
- Sarmati L, d'Ettore G, Nicastrì E, Ercoli L, Uccella I, Massetti P, Parisi SG, Vullo V, Andreoni M. Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment. *Clin Diagn Lab Immunol*. 2001;8(4):822-Sarmati L, Nicastrì E, Parisi SG, d'Ettore G, Mancino G, Narciso P, Vullo V, Andreoni M. Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells. *J Clin Microbiol*. 2002;40(2):335-40.
- Sarmati L, Nicastrì E, Uccella I, D'Ettore G, Parisi SG, Palmisano L, Galluzzo C, Concia E, Vullo V, Vella S, Andreoni M. Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing. *J Clin Microbiol*. 2003;41(4):1760-2.
- Sarmati L, Parisi SG, Nicastrì E, d'Ettore G, Palmisano L, Andreotti M, Andreoni C, Giuliano M, Gatti F, Boldrin C, Palù G, Vullo V, Vella S, Andreoni M. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy. *J Clin Microbiol*. 2005;43(12): 6183-5.
- Dagna L, Broccolo F, Paties CT, Ferrarini M, Sarmati L, Praderio L, Sabbadini MG, Lusso P, Malnati MS. A relapsing inflammatory syndrome and active human herpesvirus 8 infection. *N Engl J Med*. 2005 Jul 14;353(2):156-63.
- Sarmati L, Parisi SG, Andreoni C, Nicastrì E, Buonomini AR, Boldrin C, Dori L, Montano M, Tommasi C, Andreis S, Vullo V, Palù G, Andreoni M. Switching of inferred tropism caused by HIV during interruption of antiretroviral therapy. *J Clin Microbiol*. 2010 Jul;48(7):2586-8.
- Sarmati L, Parisi SG, Montano M, Andreis S, Scaggiante R, Galgani A, Viscione M, Maffongelli G, Ricciardi A, Andreoni C, Boros S, Palù G, Andreoni M. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain. *J Antimicrob Chemother*. 2012 ;67(12):2932-8.
- Delle Rose D, Sordillo P, Gini S, Cerva C, Boros S, Rezza G, Meledandri M, Gallo MT, Prignano G, Caccese R, D'Ambrosio M, Citterio G, Rocco M, Leonardis F, Natoli S, Fontana C, Favaro M, Celeste MG, Franci T, Testore GP, Andreoni M, Sarmati L. Microbiologic characteristics and predictors of mortality in bloodstream infections in intensive care unit patients: A 1-year, large, prospective surveillance study in 5 Italian hospitals. *Am J Infect Control*. 2015;43(11):1178-83.
- Maffongelli G, Alteri C, Gentilotti E, Bertoli A, Ricciardi A, Malagnino V, Svicher V, Santoro MM, Dori L, Perno CF, Andreoni M, Sarmati L. Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy. *AIDS*. 2016 Mar 13;30(5):731-41.
- Andreoni M, Teti E, Antinori A, Milazzo L, Sollima S, Rizzardini G, Di Biagio A, Saracino A, Bruno R, Borghi V, De Luca A, Cattelan A, Hasson H, Taliani G, Monforte AD, Mastroianni CM, Di Perri G, Bigoni S, Puoti M, Spinetti A, Gori A, Boffa N, Bruno C, Giacometti A, Parruti G, Vullo V, Chirrianni A, Pennica A, Pasquazzi C, Segala D, Sarmati L; SIMIT (Società Italiana di Malattie Infettive e Tropicali). Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. *Clin Infect Dis*. 2017 ;64(5):680-683.
- Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, Gaeta GB, Galli M, Girmenia C, Mikulska M, Pane F, Perno CF, Picardi M, Puoti M, Rambaldi A, Svicher V, Taliani G, Gentile G. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. *Clin Microbiol Infect*. 2017; 23(12):935-940.
- Gentile G, Andreoni M, Antonelli G, Sarmati L. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. *Clin Microbiol Infect*. 2017 Dec;23(12):916-923
- Malagnino V, Salpini R, Maffongelli G, Battisti A, Fabeni L, Piermatteo L, Colagrossi L, Fini V, Ricciardi A, Sarrecchia C, Perno CF, Andreoni M, Svicher V, Sarmati L. High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance. *PLoS One*. 2018 Mar 29;13(3):e0195045.
- Malagnino V, Cerva C, Maffongelli G, Teti E, Foroghi Biland L, Cesta N, De Masi M, Stingone C, Armenia D, Svicher V, Salpini R, Andreoni M, Sarmati L. HbcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy. *Sci Rep*. 2019; 16;9(1):11942.

- Iannetta M, Cesta N, Stingone C, Malagnino V, Teti E, Vitale P, De Simone G, Rossi B, Ansaldo L, Compagno M, Spalliera I, Di Lorenzo A, Landi D, Nicoletti CG, Marfia GA, Andreoni M, Sarmati L. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. *Mult Scler Relat Disord.* 2020;45:102442.
- Andreoni M, Sticchi L, Nozza S, Sarmati L, Gori A, Tavio M; Society for Infectious and Tropical Diseases (SIMIT). Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations. *Hum Vaccin Immunother.* 2021 Nov 2;17(11):4265-4282
- Iannetta M, Landi D, Cola G, Malagnino V, Teti E, Fraboni D, Buccisano F, Grelli S, Coppola L, Campogiani L, Andreoni M, Marfia GA, Sarmati L. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers. *Mult Scler Relat Disord.* 2021 Oct;55:103157.
- Iannetta M, Buccisano F, Fraboni D, Malagnino V, Campogiani L, Teti E, Spalliera I, Rossi B, Di Lorenzo A, Palmieri R, Crea A, Zordan M, Vitale P, Voso MT, Andreoni M, Sarmati L. Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study. *Sci Rep.* 2021 Jun 17;11(1):12762.
- Piermatteo L, Scutari R, Chirichiello R, Alkhatib M, Malagnino V, Bertoli A, Iapadre N, Ciotti M, Sarmati L, Andreoni M, Ceccherini-Silberstein F, Salpini R, Svicher V. Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment. *Methods.* 2021 May 14:S1046-2023(21)00137-7.
- Basso M, Zago D, Scaggiante R, Cavinato S, Pozzetto I, Stagni C, Parisatto B, Cattelan AM, Battagin G, Sarmati L, Parisi SG. HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection. *Sci Rep.* 2021 Apr 29;11(1):927420:
- Cesta N, Foroghi Biland L, Neri B, Mossa M, Campogiani L, Caldara F, Zordan M, Petruzzello C, Monteleone G, Fontana C, Andreoni M, Sarmati L. Multiple hepatic and brain abscesses caused by *Parvimonas micra*: A case report and literature review. *Anaerobe.* 2021 Jun;69:102366.
- Malagnino V, Teti E, Compagno M, Coppola L, Salpini R, Svicher V, Basso M, Battagin G, Panese S, Rossi MC, Scaggiante R, Zago D, Iannetta M, Parisi SG, Andreoni M, Sarmati L. HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort. *Microorganisms.* 2021 Feb 15;9(2):396
- Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, De Rosa FG, Sarmati L, Bassetti M, Brindicci G, Rossi M, Luzzati R, Grossi PA, Corona A, Capone A, Falcone M, Mussini C, Trecarichi EM, Cascio A, Guffanti E, Russo A, De Pascale G, Tascini C, Gentile I, Losito AR, Bussini L, Corti G, Ceccarelli G, Corcione S, Compagno M, Giacobbe DR, Saracino A, Fantoni M, Antinori S, Peghin M, Bonfanti P, Oliva A, De Gasperi A, Tiseo G, Rovelli C, Meschiari M, Shbaklo N, Spanu T, Cauda R, Viale P. Ceftazidime-Avibactam Use for *Klebsiella pneumoniae* Carbapenemase-Producing *K. pneumoniae* Infections: A Retrospective Observational Multicenter Study. *Clin Infect Dis.* 2021 2;73(9):1664-1676.
- Malagnino V, Cerva C, Teti E, Campogiani L, Compagno M, Foroghi Biland L, Saderi L, Armenia D, Salpini R, Svicher V, Sotgiu G, Iannetta M, Andreoni M, Sarmati L. Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers. *Sci Rep.* 2021 Feb 17;11(1):3965.
- Malagnino V, Cerva C, Cingolani A, Ceccherini-Silberstein F, Vergori A, Cuomo G, Perno CF, Puoti M, d'Arminio Monforte A, Cozzi-Leprì A, Andreoni M, Sarmati L; ICONA Foundation Study Group. HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. *Open Forum Infect Dis.* 2020
- Svicher V, Sarmati L. Editorial: Novel Concepts in Mechanisms Modulating HBV Persistence, Pathogenesis, and Oncogenetic Properties. *Front Microbiol.* 2021 24;12:822813.
- Fontana C, Favaro M, Campogiani L, Malagnino V, Minelli S, Bossa MC, Altieri A, Andreoni M, Sarmati L. Ceftazidime/Avibactam-Resistant *Klebsiella pneumoniae* subsp. *pneumoniae* isolates in a Tertiary Italian Hospital: Identification of a New Mutation of the Carbapenemase Type 3 (KPC-3) Gene Conferring Ceftazidime/Avibactam Resistance. *Microorganisms.* 2021 Nov 15;9(11):2356.
- Piermatteo L, Alkhatib M, D'Anna S, Malagnino V, Bertoli A, Andreassi E, Basile E, Iuvara A, De Cristofaro M, Cappiello G, Cerva C, Minichini C, Pisaturo M, Starace M, Coppola N, Fontana C, Grelli S, Ceccherini-Silberstein F, Andreoni M, Gill US, Kennedy PTF, Sarmati L, Salpini R, Svicher V. HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. *Biomedicines.* 2021 29;9(10):1352.
-

Rome March 15 th , 2023